Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies

Comparison of integrated white blood cell alpha-galactosidase a activity exposure between every-other-day orally administered migalastat and biweekly infusions of agalsidase beta or agalsidase alfa

(2016) Franklin K. Johnson et al.   MOLECULAR GENETICS AND METABOLISM

Lyso-Gb3 activates Notch1 in human podocytes

(2015) Maria D. Sanchez-Niño et al.   HUMAN MOLECULAR GENETICS

Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment

(2015) Christoph Kampmann et al.   Orphanet Journal of Rare Diseases

Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease

(2014) Andrew S Talbot et al.   HEART

Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study

(2014) L. J. Anderson et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis

(2014) Saskia M. Rombach et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Safety and effect of open-label agalsidase alfa in treatment-naïve children with Fabry disease

(2014) Arian Pano et al.   MOLECULAR GENETICS AND METABOLISM

Outcomes of patients treated through the Canadian Fabry disease initiative

(2014) S.M. Sirrs et al.   MOLECULAR GENETICS AND METABOLISM

Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study

(2014) Raphael Schiffmann et al.   Orphanet Journal of Rare Diseases

An alternative approach to deal with the absence of clinical trials: a proportional meta-analysis of case series studies

(2013) Regina El Dib et al.   Acta Cirurgica Brasileira

Demographic characterization of Brazilian patients enrolled in the Fabry Registry

(2013) A.M. Martins et al.   GENETICS AND MOLECULAR RESEARCH

Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry

(2013) Dominique P. Germain et al.   GENETICS IN MEDICINE

Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications

(2013) F. Weidemann et al.   JOURNAL OF INTERNAL MEDICINE

Early initiation of agalsidase beta treatment is associated with fewer clinical events in women with Fabry disease: Data from the Fabry Registry

(2013) Robert Hopkin et al.   MOLECULAR GENETICS AND METABOLISM

Evaluation of long-term enzyme replacement therapy for children with Fabry disease

(2013) Amanda Hebert et al.   MOLECULAR GENETICS AND METABOLISM

Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease

(2013) T. Prabakaran et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain

(2013) Saskia M Rombach et al.   Orphanet Journal of Rare Diseases

Cryoablation vs radiofrequency ablation for the treatment of renal cell carcinoma: a meta-analysis of case series studies

(2012) Regina El Dib et al.   BJU INTERNATIONAL

Fabry disease in children: agalsidase-beta enzyme replacement therapy

(2012) L Borgwardt et al.   CLINICAL GENETICS

The Effectiveness of Long-Term Agalsidase Alfa Therapy in the Treatment of Fabry Nephropathy

(2012) S. Feriozzi et al.   Clinical Journal of the American Society of Nephrology

P08—Quality of Life did not Worsen for 7 Years in Enzyme-Replacement Therapy Recipients with Fabry Disease

(2012) I. Kantola et al.   CLINICAL THERAPEUTICS

Systematic reviews showed insufficient evidence for clinical practice in 2004: what about in 2011? The next appeal for the evidence-based medicine age

(2012) Paulo José Fortes Villas Boas et al.   JOURNAL OF EVALUATION IN CLINICAL PRACTICE

Agalsidase Benefits Renal Histology in Young Patients with Fabry Disease

(2012) C. Tondel et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Fabry Registry Data Indicate that Early Initiation of Agalsidase Beta Treatment is Associated with Fewer Clinical Events

(2012) Robert Hopkin et al.   MOLECULAR GENETICS AND METABOLISM

Enzyme replacement therapy improves cardiac features and severity of Fabry disease

(2012) Manish Motwani et al.   MOLECULAR GENETICS AND METABOLISM

Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey

(2011) U Ramaswami et al.   CLINICAL GENETICS

Fabry disease in Spain: description of Spanish patients and a comparison with other European countries using data from the Fabry Outcome Survey (FOS)

(2011) M.-Á. Barba-Romero et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Cardiovascular Events in Patients With Fabry Disease

(2011) Manesh R. Patel et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Response of women with Fabry disease to enzyme replacement therapy: Comparison with men, using data from FOS—the Fabry Outcome Survey

(2011) Derralynn A. Hughes et al.   MOLECULAR GENETICS AND METABOLISM

Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation

(2011) D. G. Warnock et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease

(2011) Cédric Collin et al.   European Journal of Preventive Cardiology

Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and  -galactosidase A activity

(2010) J. C. Wu et al.   EUROPEAN HEART JOURNAL

Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry

(2010) Torquil Watt et al.   GENETICS IN MEDICINE

Enzyme replacement therapy improves cardiovascular responses to orthostatic challenge in Fabry patients

(2010) Max J Hilz et al.   JOURNAL OF HYPERTENSION

Meta-Analysis of Genome-wide Association Studies with Overlapping Subjects

(2009) Dan-Yu Lin et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Enzyme replacement therapy with agalsidase alfa in a cohort of Italian patients with Anderson-Fabry disease: testing the effects with the Mainz Severity Score Index

(2009) R Parini et al.   CLINICAL GENETICS

Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease

(2009) Jean-Claude Lubanda et al.   GENETICS IN MEDICINE

A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease

(2009) Catharina Whybra et al.   GENETICS IN MEDICINE

Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study

(2009) M Imbriaco et al.   HEART

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data

(2009) A Mehta et al.   LANCET

End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry

(2009) A. Ortiz et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy

(2009) R. Schiffmann et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Kidney Function and 24-Hour Proteinuria in Patients with Fabry Disease during 36 Months of Agalsidase Alfa Enzyme Replacement Therapy: A Brazilian Experience

(2009) Scheila Thofehrn et al.   RENAL FAILURE

Stroke in Fabry Disease Frequently Occurs Before Diagnosis and in the Absence of Other Clinical Events

(2009) Katherine Sims et al.   STROKE

Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement

(2008) T. Lobo et al.   INTERNAL MEDICINE JOURNAL

Onset and progression of the Anderson–Fabry disease related cardiomyopathy

(2008) Christoph Kampmann et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Clinical manifestations and natural history of Japanese heterozygous females with Fabry disease

(2008) M. Kobayashi et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Twenty-four-month α-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters

(2008) J. W. Koskenvuo et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Short-Term Efficacy of Enzyme Replacement Therapy in Korean Patients with Fabry Disease

(2008) Jin-Ho Choi et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3

(2008) Anouk C. Vedder et al.   MOLECULAR GENETICS AND METABOLISM

Elevated globotriaosylsphingosine is a hallmark of Fabry disease

(2008) J. M. Aerts et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety and Efficacy of Enzyme Replacement Therapy with Agalsidase Beta: An International, Open-label Study in Pediatric Patients with Fabry Disease

(2007) J. Edmond Wraith et al.   JOURNAL OF PEDIATRICS